MedDataX Logo

Effects of X-STOP® Versus Laminectomy Study

NCT ID: NCT00558129

Last Updated: 2017-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Clinical Phase

PHASE4

Study Classification

INTERVENTIONAL

Study Start Date

2007-11-30

Study Completion Date

2011-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine if the effectiveness of the X-STOP® implant is equivalent (non-inferior) to that of conventional laminectomy in patients with lumbar spinal stenosis as measured by the Zurich Claudication Questionnaire.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The clinical study described herein aims to compare surgical outcomes of X-STOP® Interspinous Process Decompression® (IPD) system implantation and conventional laminectomy in subjects requiring surgical intervention due to symptoms of lumbar spinal stenosis (LSS) and a confirmed diagnosis on MRI, X-ray or CT. Patients with LSS meeting entry criteria will be randomized to either X-STOP® IPD or laminectomy treatment. Patients will remain blinded to the procedure received. The primary study outcome is group differences in the Zurich Claudication Questionnaire (ZCQ) at 12 months post-operative. In addition, each subject will undergo follow-up assessment at 2 weeks and 2, 12 and 24 months post-operative. The secondary objective is to compare safety profiles and the radiographic outcomes between groups using pre- and post-operative MRI and flexion/extension X-rays, to measure changes in canal and neuroforaminal cross sectional areas and spinal stability, respectively.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lumbar Spinal Stenosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Lumbar Spinal Stenosis X-STOP® IPD Interspinous process decompression Neurogenic Intermittent Claudication

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Investigational

X-STOP® PEEK IPD

Group Type EXPERIMENTAL

X-STOP®

Intervention Type DEVICE

Surgical implantation of X-STOP IPD device

Control

Laminectomy

Group Type ACTIVE_COMPARATOR

Laminectomy

Intervention Type PROCEDURE

Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

X-STOP®

Surgical implantation of X-STOP IPD device

Intervention Type DEVICE

Laminectomy

Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

X-STOP® PEEK IPD

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Age \> 50
2. Has completed at least 6 months of conservative therapy which may include but is not limited to epidural steroid injection, oral steroids, NSAIDS, analgesics, physical therapy, and/or spinal manipulation.
3. Symptoms of leg/buttock/groin pain with or without back pain that are exacerbated by lumbar extension and relieved in flexion. If back pain is also present it must be partially relieved when the patient flexes.
4. Diagnosis of NIC due to lumbar stenosis at 1 or 2 lumbar levels confirmed by X-ray, MRI or CT.
5. Subject is a surgical candidate with disease severity justifying that BOTH laminectomy and X-STOP IPD placement are clinically appropriate treatment options.
7. Subject is able to walk at least 50 feet.
8. Subject is willing and able to comply with required follow-up testing and expected to be physically able to return for evaluation at scheduled follow-up visits.
9. Subject is able to understand the risks and benefits of participating in the study.
10. Subject understands and has signed the study informed consent form.

Exclusion Criteria

1. Spinal stenosis involving more than 2 lumbar levels.
2. Any previous lumbar spine surgery.
3. Subject has unremitting pain in any spinal position or axial back pain only without leg/buttock/groin pain.
4. Evidence that subject's symptoms are due to vascular claudication.
5. Subject has significant instability of the lumbar spine, e.g., isthmic spondylolisthesis or degenerative spondylolisthesis greater than Grade 1 (on a scale of 1 to 4).
6. Subject has an ankylosed segment at the affected level(s).
7. Subject has significant scoliosis (Cobb angle is greater than 25 degrees).
8. Subject has cauda equina syndrome defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder (bladder retention or incontinence) dysfunction.
9. Subject has a fixed motor deficit or known peripheral neuropathy.
10. Subject has a degenerative neurologic disease.
11. Subject has any mass lesions (e.g. disc herniations, synovial cysts, spinal tumors).
12. Any evidence of spinal or systemic infection.
13. Subject has a history of spinous process fracture or pars interarticularis fracture.
14. Subject has history or radiographic evidence of 1 or more osteoporotic fractures (e.g., vertebral, hip, wrist) OR subject has severe osteoporosis of the spine or hip, defined as bone mineral density (BMD) in the spine or hip more than 2.5 SD below the mean of adult normals. If the Investigator suspects osteoporosis, a DEXA scan should be done.
15. Subject has a known allergy to the implant materials (this includes titanium or titanium alloy and polyetheretherketone for X-STOP IPD).
16. Subject has a bleeding disorder or an active systemic disease such as HIV, hepatitis, etc.
17. Subject has any medical condition that would limit availability for follow-up.
18. Subject has a recent history of narcotic abuse (i.e., within last 3 years).
19. Subject is immunologically suppressed, or has received or is receiving 7.5 milligrams prednisone (or equivalent) daily for more than six months immediately prior to enrollment.
20. Subject is currently involved in a study of another investigational product that may affect the outcome of this study.
21. Subject is not able to undergo MRI or tolerate closed MRI scanning. Subject is pregnant or of child-bearing potential and not currently on adequate birth control method.
22. Subject is pregnant or of child-bearing potential and not currently on adequate birth control method.
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Spine LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Volker Sonntag, MD

Role: PRINCIPAL_INVESTIGATOR

Barrow Neurological Institute, St. Joseph's Hospital and Medical Center

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LSS0702

Identifier Type: -

Identifier Source: org_study_id